11.09.202505:48:03UTC+00Trump Considers Curbs on Chinese Drug Trials

According to the New York Times, the Trump administration is contemplating significant limitations on the increasing influx of pharmaceuticals from China. A draft executive order, currently under review by pharmaceutical companies and investors, accuses China and other potentially adversarial entities of taking advantage of weaknesses in the United States' scientific and regulatory frameworks. The proposed measures suggest that the FDA would impose more rigorous reviews and higher fees on clinical trial data originating from China. Additionally, there is a push to increase domestic production of essential medications, such as antibiotics and acetaminophen, with a preference for U.S.-manufactured products in government procurement. The discussions also include the possibility of accelerating FDA review processes to enable quicker initiation of drug studies, in a manner similar to China's recent regulatory updates. China has become a major player in biotech innovation, contributing to 32% of the global outlicensing deal value in early 2025, a notable increase from 21% over the previous two years.